Literature DB >> 24385089

JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis.

Ugo Fiocco1, Benedetta Accordi, Veronica Martini, Francesca Oliviero, Monica Facco, Anna Cabrelle, Lucia Piva, Beatrice Molena, Francesco Caso, Luisa Costa, Anna Scanu, Elisa Pagnin, Mariangela Atteno, Raffaele Scarpa, Giuseppe Basso, Gianpietro Semenzato, Leonardo Punzi, Andrea Doria, Jean-Michel Dayer.   

Abstract

Looking to the sustained psoriatic arthritis (PsA) joint as a model of local human inflammation, this study was designed to assess the T lymphocyte signal transduction pathways potentially involved in this chronic immune-mediated inflammatory process, as characterized by direct ex vivo analysis of T helper (Th)-17 T effector (Teff) cell phenotypes in synovial fluid (SF) and peripheral blood (PB) of clinically active PsA patients. The reverse-phase protein arrays (RPPA) technique was employed to identify STAT3, STAT1, JAK1, JAK2, PKCδ and ERK1/2 phosphoprotein levels on total T cell lysates in SF samples of PsA patients. Frequencies of T CD4(+)IL-17A-F(+) and T CD4(+)IL-23R(+) Th17 cells were quantified in SF and matched PB of PsA patients by flow cytometry and compared with PB of healthy controls (HC). Increased levels of JAK1, STAT3, STAT1 and PKCδ phosphoproteins were found in SF T cells of PsA patients, compared with PB of HC. The expansion of T CD4(+)IL-17A-F(+) cells, as well as of T CD4(+) cells expressing IL-23Rp19 (T CD4(+) IL-23R(+)), considered as the pathogenic phenotype of effector Th17 cells, was found to be confined to the joints of PsA patients, as the frequencies of both populations were significantly higher in SF than in matched PB, or in PB of HC. In conclusion, T lymphocyte signal transduction pathway mapping revealed an enhanced activation of JAK1/STAT3/STAT1 and PKCδ phosphoproteins that may drive the local inflammatory process, characterized by the in vivo expansion of T CD4(+)IL-17A-F(+) and T CD4(+)IL-23R(+) Th17 Teff cells in SF of clinically active joints of PsA patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385089     DOI: 10.1007/s12026-013-8481-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  58 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

3.  Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner.

Authors:  N Jain; T Zhang; W H Kee; W Li; X Cao
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

4.  c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection.

Authors:  Katharina Reinhard; Magdalena Huber; Corinna Wostl; Anne Hellhund; Anne Toboldt; Elfadil Abass; Bärbel Casper; Thorsten Joeris; Christian Herr; Robert Bals; Ulrich Steinhoff; Michael Lohoff; Alexander Visekruna
Journal:  Eur J Immunol       Date:  2011-04-11       Impact factor: 5.532

Review 5.  Innate IL-17-producing cells: the sentinels of the immune system.

Authors:  Daniel J Cua; Cristina M Tato
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

6.  Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression.

Authors:  Wendy A Goodman; Andrew B Young; Thomas S McCormick; Kevin D Cooper; Alan D Levine
Journal:  J Immunol       Date:  2011-02-09       Impact factor: 5.422

Review 7.  Genomic views of STAT function in CD4+ T helper cell differentiation.

Authors:  John J O'Shea; Riitta Lahesmaa; Golnaz Vahedi; Arian Laurence; Yuka Kanno
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

8.  Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Authors:  Benedetta Accordi; Virginia Espina; Marco Giordan; Amy VanMeter; Gloria Milani; Luisa Galla; Maria Ruzzene; Manuela Sciro; Luca Trentin; Ruggero De Maria; Geertruy te Kronnie; Emanuel Petricoin; Lance Liotta; Giuseppe Basso
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103

10.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

View more
  20 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Transcriptional network profile on synovial fluid T cells in psoriatic arthritis.

Authors:  Ugo Fiocco; Veronica Martini; Benedetta Accordi; Francesco Caso; Luisa Costa; Francesca Oliviero; Anna Scanu; Monica Facco; Daniele Boso; Mariele Gatto; Mara Felicetti; Paola Frallonardo; Roberta Ramonda; Lucia Piva; Renato Zambello; Carlo Agostini; Raffaele Scarpa; Giuseppe Basso; Gianpietro Semenzato; Jean-Michel Dayer; Leonardo Punzi; Andrea Doria
Journal:  Clin Rheumatol       Date:  2015-07-09       Impact factor: 2.980

Review 4.  Psoriatic arthritis: latest treatments and their place in therapy.

Authors:  Eun Jin Kang; Arthur Kavanaugh
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

Review 5.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

6.  Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".

Authors:  Matteo Megna; Anna Balato; Maddalena Napolitano; Lucia Gallo; Francesco Caso; Luisa Costa; Nicola Balato; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2018-04-11       Impact factor: 2.980

7.  A specific small-molecule inhibitor of protein kinase CδI activity improves metabolic dysfunction in human adipocytes from obese individuals.

Authors:  Robert Sparks; Ashley Lui; Deena Bader; Rekha Patel; Michel Murr; Wayne Guida; Rutilio Fratti; Niketa A Patel
Journal:  J Biol Chem       Date:  2019-08-14       Impact factor: 5.157

8.  Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints.

Authors:  Ugo Fiocco; Roberto Stramare; Veronica Martini; Alessandro Coran; Francesco Caso; Luisa Costa; Mara Felicetti; Gaia Rizzo; Matteo Tonietto; Anna Scanu; Francesca Oliviero; Bernd Raffeiner; Maristella Vezzù; Francesca Lunardi; Raffaele Scarpa; David Sacerdoti; Leopoldo Rubaltelli; Leonardo Punzi; Andrea Doria; Enrico Grisan
Journal:  Clin Rheumatol       Date:  2016-12-20       Impact factor: 2.980

Review 9.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

10.  Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.

Authors:  Luisa Costa; Francesco Caso; Luca Cantarini; Antonio Del Puente; Raffaele Scarpa; Mariangela Atteno
Journal:  Clin Rheumatol       Date:  2014-04-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.